All In Biotech

Drug Trial Radar · NCT03754049

A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee

A Phase 2, Open-label, Pharmacokinetic (PK) Study of a Single Intra-articular Administration of TLC599 in Subjects With Mild to Moderate Osteoarthritis of the Knee

Last checked: Nov 19, 2026Latest source record: Oct 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

102

Actual

Start

Jan 21, 2019

Primary completion

Nov 7, 2023

Study completion Nov 7, 2023

Sponsor

Lead sponsor
Taiwan Liposome CompanyIndustry
Sponsor type
Industry
First posted
Nov 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a multi-center, Phase 2, open-label, 1-period, parallel study with 9 cohorts of subjects with osteoarthritis (OA) of the knee enrolled to receive single-dose of TLC599 or Dexamethasone sodium phosphate (DSP) via IA injection and 1 cohort of healthy subjects to receive single-dose of DSP via intravenous (IV) injection.

Conditions

  • Osteoarthritis of the Knee

Interventions

  • TLC599Drug

    TLC599 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP (active ingredient).

  • DSPDrug

    Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the Curve [AUC]Time frame: Baseline till 24 weeks post investigational product (IP) administration
  2. Cmax: maximum concentrationTime frame: Baseline till 24 weeks post IP administration
  3. Tmax: time to peak concentrationTime frame: Baseline till 24 weeks post IP administration

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Arizona Research Center

    Phoenix, Arizona

  • Panax Clinical Research

    Miami, Florida

  • South Coast Research Center

    Miami, Florida

  • Syneos Health

    Miami, Florida

  • Clinical Trials of South Carolina

    Charleston, South Carolina

  • Futuro Clinical Trials, LLC.

    McAllen, Texas

  • JBR Clinical Research

    Salt Lake City, Utah

  • China Medical University Hospital

    Taichung, Taiwan

  • Tri-Service General Hospital

    Taipei, Taiwan

  • Taipei Municipal Wanfang Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.